MiNK Therapeutics, Inc.
INKT
Rank in Stocks
#22520
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing... MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Share Price
$10.30
Last synced: 2026-11-09
Market Cap
$52.54M
Change (1 day)
-0.53%
Change (1 year)
-24.63%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MiNK Therapeutics, Inc. (INKT)
Category
Healthcare
Operating Margin for MiNK Therapeutics, Inc. (INKT)
Operating Margin as of November 2026 TTM: 0.00%
According to MiNK Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for MiNK Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -3,231.39% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MiNK Therapeutics, Inc.'s operating margin
What was MiNK Therapeutics, Inc.'s operating margin in 2025?
In 2025, MiNK Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has MiNK Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, MiNK Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does MiNK Therapeutics, Inc.'s operating margin compare with similar companies?
MiNK Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.